New daraxonrasib pancreatic cancer data suggest Revolution Medicines’ RAS(ON) inhibitor could reshape first-line treatment. Updated Phase 1/2 results from the RMC-GI-102 study, presented at the EORTC-NCI-AACR (ENA) Symposium in Barcelona on 20 November 2026, showed that daraxonrasib (brand name Rasonque) plus gemcitabine and nab-paclitaxel shrank tumours in 60.7% of 61 previously untreated patients with metastatic pancreatic cancer, with a median progression-free survival of 12.8 months and 76.6% of patients alive at one year.
Key takeaways on daraxonrasib in pancreatic cancer
- Rasonque is already approved in the US as a single agent for metastatic pancreatic cancer after prior therapy; these data test it earlier, combined with standard chemotherapy.
- Confirmed objective response rate was 60.7%, including 8.2% complete responses, and 90.2% of patients had disease control.
- Median response duration was 11.1 months and median progression-free survival 12.8 months after 18.3 months of median follow-up.
- The study had no control arm, so it cannot prove a survival advantage; the randomized Phase 3 RASolute 303 trial will answer that.
- The FDA granted Breakthrough Therapy Designation to the first-line combination in September 2026.
Why first-line matters in pancreatic cancer
Pancreatic ductal adenocarcinoma is among the deadliest common cancers, and more than nine in ten tumours carry a mutation in a RAS gene, most often KRAS G12D or G12V. For decades, the first-line options have been combination chemotherapy regimens such as gemcitabine with nab-paclitaxel (GnP) or FOLFIRINOX. Daraxonrasib is designed to block the active, “ON” form of multiple RAS variants rather than a single mutation, which is why it can be tested across the whole disease rather than in a narrow subgroup.
Its US approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who cannot have multi-agent treatment, based on the RASolute 302 trial. Moving into first line, where patients are fitter and tumours less resistant, is where the largest benefit and the largest commercial opportunity lie.
RMC-GI-102 first-line results at a glance
| Endpoint (n=61, daraxonrasib 200 mg + GnP) | Result | 95% CI |
|---|---|---|
| Confirmed objective response rate | 60.7% | 47.3 to 72.9 |
| Complete response | 8.2% | n/a |
| Disease control rate | 90.2% | 79.8 to 96.3 |
| Median duration of response | 11.1 months | 7.6 to 18.4 |
| Median progression-free survival | 12.8 months | 10.8 to 18.4 |
| Overall survival at 12 months | 76.6% | 63.7 to 85.4 |
The update builds on an earlier AACR 2026 readout of 40 patients, which showed a confirmed response rate of 58% and a 2.5% complete response rate. With longer follow-up, the complete response rate has risen to 8.2%, a notable figure in a disease where complete responses are rare. Presenter Wungki Park of Memorial Sloan Kettering said the “emerging survival signal is meaningful.”
How strong is the evidence?
Analysts at Truist Securities note that chemotherapy alone has historically delivered median overall survival of roughly 8.5 to 11 months in this setting, and they had expected median PFS of around 10 months for the combination. The 12.8-month PFS beat that expectation. However, a 12-month survival rate cannot be compared directly with a historical median, and single-arm studies often look better than randomized ones because of patient selection. Median overall survival has not yet been reported. Truist itself cautioned that response rates alone are unlikely to settle the competitive debate.
Safety remains the other open question. In the earlier AACR analysis of 40 patients, grade 3 or higher treatment-related adverse events occurred in 73%, with rash (90%), diarrhoea (75%), fatigue (70%) and nausea (68%) the most common side effects of any grade, grade 3 or higher anaemia in 33%, and dose reductions in 35%. There were no treatment-related deaths. Revolution Medicines says safety in the updated cohort was consistent with the known profiles of each drug, and Leerink analysts called tolerability manageable.
RASolute 303 and the RAS race
The definitive test is RASolute 303 (NCT07491445), a randomized Phase 3 comparing daraxonrasib alone and daraxonrasib plus GnP with GnP alone in untreated metastatic pancreatic cancer, regardless of RAS genotype. Truist expects a readout around 2028, which would put a first-line approval no earlier than that year.
Competition is building. On the same day, Erasca presented early data for its pan-RAS molecular glue ERAS-0015, which we covered in ERAS-0015 shrinks tumours in 44% of pretreated pancreatic cancer patients, and Revolution Medicines has filed patent litigation against Erasca. Roche’s KRAS G12C drug divarasib, covered in our divarasib Phase 3 report, shows how quickly RAS-targeted drugs are moving across tumour types. Rasonque booked $198 million in its first quarter on the market, and Truist estimates peak sales could reach $14.5 billion. More updates are in our oncology section.
Market context
According to Acumen Research and Consulting, the global pancreatic cancer therapeutics market was valued at USD 3,582 million in 2021 and is expected to reach USD 6,575 million by 2030, a CAGR of 7.2%, with North America the largest region and Asia-Pacific the fastest growing. That forecast dates from 2022, before RAS(ON) inhibitors reached the market, so it should be read as indicative. By our calculation, a single drug reaching Truist’s peak-sales estimate would exceed the entire 2030 market Acumen projected, a sign of how targeted therapy could expand spending in this disease.
Questions patients and readers are asking
What is daraxonrasib (Rasonque)?
Daraxonrasib is an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, sold as Rasonque. It is approved in the US for metastatic pancreatic cancer after prior treatment.
Is daraxonrasib approved as a first-line pancreatic cancer treatment?
No. The first-line combination with gemcitabine and nab-paclitaxel has Breakthrough Therapy Designation but is still being tested in the Phase 3 RASolute 303 trial.
Does daraxonrasib improve survival in pancreatic cancer?
In this single-arm first-line study, 76.6% of patients were alive at 12 months, which is encouraging but not proof. A randomized comparison with chemotherapy alone is needed to confirm a survival benefit in first line.
Sources: Revolution Medicines ENA 2026 release; Targeted Oncology; BioSpace; ClinicalTrials.gov NCT07491445. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 20 November 2026.

[…] Loss Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning Daraxonrasib in First-Line Pancreatic Cancer: 60.7% Response With Chemotherapy Efsubaglutide Alfa: Innogen’s $1 Billion GLP-1 Deal Takes China’s Long-Acting Drug to […]